Insulin Resistance And End Stage Renal Disease: The Role Of Retinol Binding Protein 4
- Conditions
- End Stage Renal DiseaseInsulin ResistanceDiabetes
- Registration Number
- NCT00910130
- Lead Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
- Brief Summary
The purpose of this study is to determine whether Retinol binding protein 4 has a role in insulin resistance development in patients suffering from end stage renal disease on hemodialysis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- Hemodialysis for "End Stage Renal Disease group"
- Normal Renal Function for "Control group"
Exclusion Criteria
- Diabetes
- Malnutrition
- Malignancy
- Acute Infection
- Chronic Active Infection
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the role of Retinol Binding Protein 4 in insulin resistance among hemodialysis patients with End Stage Renal Disease?
How does Retinol Binding Protein 4 correlate with metabolic syndrome in End Stage Renal Disease patients on dialysis?
Are there specific biomarkers that link Retinol Binding Protein 4 levels to diabetes progression in chronic kidney disease populations?
What molecular pathways involving Retinol Binding Protein 4 contribute to glucose metabolism impairment in renal failure?
How effective are current insulin-sensitizing agents compared to targeting Retinol Binding Protein 4 in managing diabetes for End Stage Renal Disease patients?
Trial Locations
- Locations (1)
Giovanni Piotti
🇮🇹Pavia, Italy